Jun 2026 (Q2 FY26) — Aug 13, 2026
Rockwell Medical Q2 FY26 — Strong Growth, Margin Expansion, and Positive Cash Flow
Read the full callRockwell Medical (RMTI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Rockwell Medical earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 17.8 | +10.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -6.0 | +2.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.98 +4.18% · +$0.32
Performance −33.5% 1Y
1Y: $12 on 14 Oct 2025 → $7.98. High $12.6 (20 Jan 2026), low $5.19 (1 Jul 2026).
- Previous close
- $7.66
- 52-week range
- $5.19 – $12.6
- One year
- −33.50%
Overview
- Symbol
- RMTI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Rockwell Medical earnings calls (RMTI)
Financials
What the filings say
Net profit, year on year: +21% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 25 | 19 | 16 | 16 | 18 | 17 | 18 |
| Operating profit | 2 | -1 | -1 | -1 | -2 | -0 | -1 | -1 |
| Operating margin | 6.8% | −2.1% | −7.2% | −8.4% | −9.9% | −2.2% | −8.5% | −6.0% |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 2 | -1 | -2 | -1 | -2 | -1 | -2 | -1 |
| EPS ($ per share) | 0.05 | — | -0.04 | -0.48 | -0.05 | — | -0.04 | -0.34 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -272 | -307 | -337 | -370 | -389 | -397 | -398 | -403 |
| Total liabilities | 25 | 24 | 44 | 46 | 33 | 31 | 27 | 20 |
| Fixed assets | 3 | 2 | 3 | 2 | 2 | 6 | 6 | 5 |
| Total assets | 53 | 44 | 78 | 49 | 47 | 52 | 59 | 57 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20 | -27 | -30 | -34 | -17 | -9 | 4 | -1 |
| Cash from investing | 13 | -5 | 3 | 0 | -2 | -3 | -5 | -9 |
| Cash from financing | 22 | 21 | 63 | -2 | 16 | 11 | 7 | 4 |
| Net cash flow | 14 | -11 | 37 | -35 | -3 | -1 | 7 | -5 |
| Capital expenditure | — | — | — | — | — | -0 | -1 | -1 |
| Free cash flow | — | — | — | — | — | -10 | 3 | -1 |
Insider filings
20 filings between Nov 17, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$16.0K
4 sales by 4 insiders
75% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
- 5
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Strobeck Mark | — | $8.4K | Oct 1, 2026 |
| COOPER JOHN G | — | $4.4K | Nov 18, 2025 |
| Hunter Heather | — | $2.4K | Jan 2, 2026 |
| Neri Jesse | — | $740 | Jan 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Strobeck Mark President and CEO | Sale 10b5-1 plan | 1,000 | $8.4K |
| Jul 1, 2026 | Neri Jesse SVP and CFO | Award | 15,000 | $0 |
| Jul 1, 2026 | TIMMINS MEGAN C. EVP, CLO & Secretary | Award | 15,000 | $0 |
| Jul 1, 2026 | Hunter Heather Chief Operating Officer | Award | 15,000 | $0 |
| Jul 1, 2026 | Chole Timothy SVP and CCO | Award | 15,000 | $0 |
| Jul 1, 2026 | COOPER JOHN G Director | Award | 9,633 | $0 |
| Jul 1, 2026 | Radie Robert S Director | Award | 9,633 | $0 |
| Jul 1, 2026 | Lau Joan Director | Award | 9,633 | $0 |
| Jul 1, 2026 | Nissenson Allen Director | Award | 9,633 | $0 |
| Jul 1, 2026 | Dawson Joseph H Director | Award | 9,633 | $0 |
| Jul 1, 2026 | Strobeck Mark President and CEO | Award | 30,000 | $0 |
| Mar 14, 2026 | Chole Timothy SVP and CCO | Tax withheld | 2,444 | $2.2K |
| Mar 14, 2026 | Neri Jesse SVP and CFO | Tax withheld | 2,444 | $2.2K |
| Mar 14, 2026 | TIMMINS MEGAN C. See Remarks | Tax withheld | 3,667 | $3.3K |
| Mar 14, 2026 | Hunter Heather Chief Operating Officer | Tax withheld | 2,444 | $2.2K |
| Mar 14, 2026 | Strobeck Mark President and CEO | Tax withheld | 7,333 | $6.6K |
| Jan 2, 2026 | Hunter Heather Chief Operating Officer | Sale 10b5-1 plan | 2,868 | $2.4K |
| Jan 2, 2026 | Neri Jesse SVP and CFO | Sale 10b5-1 plan | 886 | $740 |
| Nov 18, 2025 | COOPER JOHN G Director | Sale | 5,079 | $4.4K |
| Nov 17, 2025 | Dawson Joseph H Director | Award | 25,000 | $0 |
| Oct 1, 2025 | Hunter Heather SVP, Chief Operating Officer | Sale 10b5-1 plan | 2,868 | $3.4K |
| Oct 1, 2025 | Neri Jesse SVP and CFO | Sale 10b5-1 plan | 886 | $1.1K |
| Oct 1, 2025 | Chole Timothy SVP and CCO | Sale 10b5-1 plan | 2,868 | $3.4K |
| Oct 1, 2025 | Strobeck Mark President and CEO | Sale 10b5-1 plan | 6,926 | $8.2K |
| Jul 1, 2025 | Strobeck Mark President and CEO | Sale 10b5-1 plan | 6,926 | $5.7K |
| Jul 1, 2025 | Chole Timothy SVP and CCO | Sale 10b5-1 plan | 2,868 | $2.4K |
| Jul 1, 2025 | Neri Jesse SVP and CFO | Sale 10b5-1 plan | 886 | $727 |
| May 20, 2025 | TIMMINS MEGAN C. EVP, CLO and Secretary | Award | 97,500 | $0 |
| May 20, 2025 | Neri Jesse SVP, FINANCE AND CFO | Award | 97,500 | $0 |
| May 20, 2025 | Chole Timothy SVP, Chief Commercial Officer | Award | 85,000 | $0 |
| May 20, 2025 | Smiley Andrea Heslin Director | Award | 50,000 | $0 |
| May 20, 2025 | Radie Robert S Director | Award | 50,000 | $0 |
| May 20, 2025 | RAVICH MARK H Director | Award | 50,000 | $0 |
| May 20, 2025 | Nissenson Allen Director | Award | 50,000 | $0 |
| May 20, 2025 | COOPER JOHN G Director | Award | 50,000 | $0 |
| May 20, 2025 | Lau Joan Director | Award | 50,000 | $0 |
| May 20, 2025 | Strobeck Mark President and CEO | Award | 220,000 | $0 |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 1,000 | $1.1K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.1K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.1K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 4,000 | $4.4K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 1,500 | $1.6K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.1K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 6,000 | $6.5K |
| Apr 11, 2025 | Irrevocable Larson Family Investment Trust 10% owner | Purchase | 2,000 | $2.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ROCKWELL MEDICAL, INC.
Free account. Everything above stays public.
Write why you follow ROCKWELL MEDICAL, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading